Cart
sales@molnova.com
Senaparib
CAS No. 1401682-78-7
Senaparib( IMP4297 )
Catalog No. M28788 CAS No. 1401682-78-7
Senaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 49 | Get Quote |
|
| 5MG | 80 | Get Quote |
|
| 10MG | 140 | Get Quote |
|
| 25MG | 260 | Get Quote |
|
| 50MG | 410 | Get Quote |
|
| 100MG | 605 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSenaparib
-
NoteResearch use only, not for human use.
-
Brief DescriptionSenaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.
-
DescriptionSenaparib is a novel highly potent and selective oral PARP1/2 inhibitor with strong antitumor activity.
-
In Vitro——
-
In Vivo——
-
SynonymsIMP4297
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
Recptorneuropeptide Y (NPY) Y1 receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1401682-78-7
-
Formula Weight478.45
-
Molecular FormulaC24H20F2N6O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (174.17 mM)
-
SMILESO=C(c(cc(CN(c1cccc(F)c1C(N1)=O)C1=O)cc1)c1F)N(CC1)CCN1c1ncccn1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Antal-Zimanyi I, et al. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist. Eur J Pharmacol. 2008 Aug 20;590(1-3):224-32.
molnova catalog
related products
-
Niraparib (R-enantio...
Niraparib R-enantiomer is an inhibitor of PARP1(IC50 of 2.4 nM).
-
TIQ-A
TIQ-A is a PARP1 inhibitor which involved in DNA single-strand break repair via the base excision repair pathway. PARP1 is triggered by DNA damage and its excessive activation has been proposed as a causative factor in many pathological conditions including ischemia and reperfusion injury, asthma-related inflammation, and atherogenesis.
-
MK-4827 hydrochlorid...
A highly potent PARP inhibitor with IC50 of 3.8 nM/2.1 nM for PARP1/PARP2.
